Recombinant human brain natriuretic peptide typically costs around$1,000. Depending on the level of the medical institution, there are some organizations that can also reach around$2,000. Recombinant human cerebral natriuretic peptide is mainly used in patients with cardiac function of grade 2 and above according to the grading method of the New York Heart Association, which clinically manifests itself as dyspnea that can occur at rest or with mild activity. Generally, recombinant human brain natriuretic peptide is used in patients with acute decompensated heart failure, because recombinant human brain natriuretic peptide can cause an increase in intracellular cyclic guanosine monophosphate concentration, and also can make smooth muscle cells diastolic, which can dilate the arterial and venous effects, and it can lower the arterial pressure of the whole body, including the pressure of the right atrium, which can lower the preload and afterload of the heart, and then achieve to alleviate the dyspnea and systemic symptoms of patients with heart failure. Dyspnea and systemic symptoms, because brain natriuretic peptide can improve the glomerular filtration rate, increase the excretion of sodium, can increase the permeability of blood vessels, while reducing the preload and afterload of the heart, increase the cardiac output.